The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia

Not Applicable

• Conditions: Subcortical Vascular Dementia; Cerebral Small Vessel Diseases
• Interventions: Drug: NBP; Drug: Placebos

• Registration Number: NCT03906123
• Lead Sponsor: Tianjin Medical University General Hospital

Brief Summary

This is a 48-week, double-blind, randomized, placebo-controlled study. Sixty-four patients are randomly assigned to take NBP (600mg per day) or placebo for 48 weeks, with 32 patients in each treatment group. Anti-dementia treatment-naive patients meet the inclusion/exclusion criteria are enrolled.

Patients are assigned to NBP will take 200mg tid daily. Patients are visited at baseline, as well as 4, 12, 24, 36, 48weeks after baseline. Safety data is recorded until an additional 30 days after the last treatment (48 weeks).

The primary outcomes include cognitive function and activities of daily living (ADL). All subjects are assessed at baseline, 4w, 12w,24w, 36w intermittent visit and 48w endpoint with the Auditory Verbal Learning Test (AVLT), the Brief Visuospatial Memory Test-Revised (BVMT-R), the Symbol Digit Modalities Test (SDMT), the Trail Making Test-A/B (TMT-A/B), the Benton Judgment of Line Orientation (JLO), the verbal fluency test, the Boston Naming Test (BNT), the Controlled Oral Word Association Test (COWAT), the Stroop test, the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA) and the ADL. The secondary outcomes include the global function and behavioral and psychological symptoms of dementia (BPSD), which are evaluated with the Clinical Dementia Rating (CDR) and the Neuropsychiatric Inventory (NPI), respectively. Independent raters who are blinded to patients' distribution are assigned to assess the participants.

The exploratory outcomes are markers of vascular regulation, including circulating endothelial progenitor cells (EPCs), white matter hyperintensities (WMH) on MRI, cerebral blood flow (CBF) measured with transcranial Doppler (TCD) and arterial spin labeling (ASL) MRI, and parameters of carotid duplex ultrasonic (CDU). In addition, apolipoprotein E (APOE) polymorphism and plasma biomarkers are also detected.

Safety are assessed at each visit.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-11-18
• Study First Submitted: 2019-03-27
• Status Verified: 2019-04
• Study First Submitted QC: 2019-04-03
• Last Update Submitted: 2019-04-03
• Study First Posted: 2019-04-08
• Last Update Posted: 2019-04-08
• Primary Completion: 2019-12-31
• Study Completion: 2020-01-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

1. Patients meet the criteria of major neurocognitive disorder in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);
2. Patients aged with 50-80 years, years of education no less than 3, an MMSE range of 15~26, an MoCA < 26, an Hamilton Depression Scale (HAMD) < 17;
3. The MRI (one research dedicated machine 3.0 T) features satisfy subcortical small vessel disease, including (1) multiple (>=3) supratentorial subcortical lacunes (3-20 mm in diameter), with/without white matter hyperintensities (WMH) of any degree; (2) moderate to severe WMH (score>= 2 according to the Fazekas rating scale in either periventricular region or deep white matter) with/without lacunes; (3) one or more strategically located subcortical small infarcts in the deep grey matters;
4. Patients or legal representative should sign the informed consent and have a reliable caregiver.

Read More

Exclusion Criteria

1. Cognitive impairment caused by other central nervous system diseases, such as AD, dementia with Lewy body, frontal-temporal lobe degeneration, etc;
2. Cognitive impairment due to other conditions, such as severe depression, vitamin B 12 deficiency, abnormal thyroid function, etc;
3. Alcoholism, drug abuse or other conditions influenced the evaluation of cognition;
4. Patients unable to undertake MRI assessment.
5. Patients with a history of other severe disease such as epilepsy, myocardial infarction or heart failure will be excluded;
6. Administration of other investigational drugs, psychotropic drugs, drugs with psychiatric side effects, and oral anticoagulants are not allowed

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
NBP	NBP	DL-3-n-butylphthalide (NBP), soft capsule, 200mg Tid, po, for 48 weeks.
Placebos	Placebos	Placebo, soft capsule, 200mg Tid, po, for 48 weeks.

Primary Outcome Measures

Name	Time	Method
Symbol Digit Modalities Test (SDMT) at endpoint and change from baseline	48 weeks post-dose and change from baseline	SDMT is used to assess information processing speed. Higher score indicates better performance.
Boston Naming Test (BNT) at endpoint and change from baseline	48 weeks post-dose and change from baseline	BNT is used to evaluate language function. Higher score indicates better performance.
Montreal Cognitive Assessment (MoCA) at endpoint and change from baseline	48 weeks post-dose and change from baseline	MoCA is used to evaluate global cognition. Higher score indicates better performance.
Auditory Verbal Learning Test (AVLT) at endpoint and change from baseline	48 weeks post-dose and change from baseline	AVLT is used to evaluate verbal learning and memory ability. Higher score indicates better performance.
Digital span (DS) at endpoint and change from baseline	48 weeks post-dose and change from baseline	DS is used to assess attention. Higher score indicates better performance.
Verbal fluency test at endpoint and change from baseline	48 weeks post-dose and change from baseline	Verbal fluency test is used to evaluate language function. Higher score indicates better performance.
Controlled Oral Word Association Test (COWAT) at endpoint and change from baseline	48 weeks post-dose and change from baseline	COWAT is used to evaluate language function. Higher score indicates better performance.
Stroop test at endpoint and change from baseline	48 weeks post-dose and change from baseline	Stroop test is used to assess executive function. Higher score indicates better performance.
Activity of daily living (ADL) at endpoint and change from baseline	48 weeks post-dose and change from baseline	ADL is used to evaluate activities of daily living.
Brief Visuospatial Memory Test-Revised (BVMT-R) at endpoint and change from baseline	48 weeks post-dose and change from baseline	BVMT-R is used to evaluate spatial memory ability. Higher score indicates better performance.
Trail Making Test-A (TMT-A) at endpoint and change from baseline	48 weeks post-dose and change from baseline	TMT-A is used to assess information processing speed. Lower score indicates better performance.
Mini-Mental State Examination (MMSE) at endpoint and change from baseline	48 weeks post-dose and change from baseline	MMSE is used to evaluate global cognition. Higher score indicates better performance.
TMT-B at endpoint and change from baseline	48 weeks post-dose and change from baseline	TMT-B is used to assess executive function. Lower score indicates better performance.
Benton Judgment of Line Orientation (JLO) at endpoint and change from baseline	48 weeks post-dose and change from baseline	JLO is used to assess visuospatial function. Higher score indicates better performance.

Secondary Outcome Measures

Name	Time	Method
Global function at endpoint and change from baseline	48 weeks post-dose and change from baseline	Clinical Dementia Rating (CDR) is used to evaluate global function.
Neuropsychiatric Inventory (NPI) at endpoint and change from baseline	48 weeks post-dose and change from baseline	NPI is used to evaluate behavioral and psychological symptoms of dementia (BPSD).

Trial Locations

Locations (1)

Tianjin Medicial University General Hospital; 🇨🇳 Tianjin, Tianjin, China